Static and dynamic pupillary features in graves disease without orbitopathy

被引:0
|
作者
Kuskonmaz, Serife Mehlika [1 ]
Kocer, Ali Mert [2 ]
Onder, Cagatay Emir [1 ]
Sekeroglu, Mehmet Ali [3 ]
机构
[1] Ankara Numune Training & Res Hosp, Dept Endocrinol & Metab Dis, Ankara, Turkiye
[2] Ulucanlar Eye Training & Res Hosp, Dept Ophthalmol, Ankara, Turkiye
[3] Bilkent City Hosp, Dept Ophthalmol, Ankara, Turkiye
关键词
Static pupillary measurements; Dynamic pupillary measurements; Thyroid eye disease; Graves disease; Hyperthyroidism; SYMPATHETIC OVERACTIVITY; PUPILLOMETRY;
D O I
10.1007/s10792-024-03355-8
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PurposePupillary contraction and dilatation are organized by the autonomic nervous system, which can also be affected by Graves' disease (GD). In this study, it was aimed to investigate the static and dynamic pupillary responses of Graves' patients in the hyperthyroid and euthyroid periods and to compare these results with the values obtained from healthy controls. Methods48 eyes of 24 newly diagnosed Graves' patients with clinical activity score <= 2 and 46 eyes of 23 age- and sex-matched healthy controls were included in the study. Patients with GD were evaluated separately in the hyperthyroid phase and after euthyroidism was achieved. After a detailed ophthalmological examination, patients undergone automatic quantitative testing to obtain static (scotopic, mesopic, low photopic, and high photopeak pupil diameters) and dynamic (pupillary contraction amplitude, latency, velocity and duration, and pupil dilation latency, velocity and duration) pupil measurements. ResultsA statistically significant difference was found between the control [4.7 mm (3.7-6.9)] and hyperthyroid [5.1 mm (3.6-7.8)] groups for mesopic pupil diameter (p = 0.003). Dynamic pupillometry measurements showed that hyperthyroid and euthyroid groups had greater pupil dilation delay and lower pupil dilation rate compared to the control group (p < 0.05 for all). ConclusionEven in the absence of orbitopathy, patients with GD have autonomic dysregulation of pupillary functions. These changes, which prevail in the hyperthyroid phase, do not reverse when the TSH receptor antibody titer drops and the patient becomes euthyroid. Future studies are needed to elucidate the mechanism of these pupillary changes in GD.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study
    Biscarini, Filippo
    Masetti, Giulia
    Muller, Ilaria
    Verhasselt, Hedda Luise
    Covelli, Danila
    Colucci, Giuseppe
    Zhang, Lei
    Draman, Mohd Shazli
    Okosieme, Onyebuchi
    Taylor, Pete
    Daumerie, Chantal
    Burlacu, Maria-Cristina
    Marino, Michele
    Ezra, Daniel George
    Perros, Petros
    Plummer, Sue
    Eckstein, Anja
    Salvi, Mario
    Marchesi, Julian R.
    Ludgate, Marian
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (08) : 2065 - 2077
  • [22] Graves’ disease and Graves’ orbitopathy following COVID-19
    G. Lanzolla
    C. Marcocci
    M. Marinò
    Journal of Endocrinological Investigation, 2021, 44 : 2011 - 2012
  • [23] The Race for New Treatments for Graves Orbitopathy (Thyroid Eye Disease)
    Dayan, Colin M.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (10) : e1938 - e1939
  • [24] Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy
    Aass, Cecilie
    Norheim, Ingrid
    Eriksen, Erik Fink
    Bornick, Ellen Charlotte
    Thorsby, Per Medboe
    Pepaj, Milaim
    PLOS ONE, 2017, 12 (04):
  • [25] Improving treatment outcomes for Graves' disease patients with inactive forms of Graves' orbitopathy through an increased dose of radioiodine therapy
    Gosmann, Janika
    Willms, Diana
    Bell, Eberhard
    Schreckenberger, Mathias
    Willms, Arnulf
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2020, 59 (03): : 260 - 268
  • [26] Changes in pupillary distance after fat versus bony orbital decompression in Graves' orbitopathy
    Woo, Young Jun
    Yoon, Jin Sook
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2017, 52 (02): : 186 - 191
  • [27] Serum thyroglobulin is associated with orbitopathy in Graves’ disease
    S. Khamisi
    M. Lundqvist
    P. Emadi
    K. Almby
    Ö. Ljunggren
    F. A. Karlsson
    Journal of Endocrinological Investigation, 2021, 44 : 1905 - 1911
  • [28] Guidance on That Damned Elusive Orbitopathy of Graves' Disease
    Laurberg, Peter
    EUROPEAN THYROID JOURNAL, 2016, 5 (01) : 4 - 6
  • [29] Teprotumumab: a disease modifying treatment for graves' orbitopathy
    Ting, Michelle
    Ezra, Daniel G.
    THYROID RESEARCH, 2020, 13 (01)
  • [30] Graves' Orbitopathy: Imperfect Treatments for a Rare Disease
    Bartalena, Luigi
    EUROPEAN THYROID JOURNAL, 2013, 2 (04) : 259 - 269